PubMed:17996686 JSONTXT

{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":129},"obj":"Sentence"},{"id":"T2","span":{"begin":130,"end":149},"obj":"Sentence"},{"id":"T3","span":{"begin":150,"end":289},"obj":"Sentence"},{"id":"T4","span":{"begin":290,"end":411},"obj":"Sentence"},{"id":"T5","span":{"begin":412,"end":678},"obj":"Sentence"},{"id":"T6","span":{"begin":679,"end":762},"obj":"Sentence"},{"id":"T7","span":{"begin":763,"end":865},"obj":"Sentence"},{"id":"T8","span":{"begin":866,"end":954},"obj":"Sentence"},{"id":"T9","span":{"begin":955,"end":963},"obj":"Sentence"},{"id":"T10","span":{"begin":964,"end":1179},"obj":"Sentence"},{"id":"T11","span":{"begin":1180,"end":1314},"obj":"Sentence"},{"id":"T12","span":{"begin":1315,"end":1455},"obj":"Sentence"},{"id":"T13","span":{"begin":1456,"end":1556},"obj":"Sentence"},{"id":"T14","span":{"begin":1557,"end":1660},"obj":"Sentence"},{"id":"T15","span":{"begin":1661,"end":1672},"obj":"Sentence"},{"id":"T16","span":{"begin":1673,"end":1794},"obj":"Sentence"},{"id":"T17","span":{"begin":1795,"end":1862},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":129},"obj":"Sentence"},{"id":"T2","span":{"begin":130,"end":149},"obj":"Sentence"},{"id":"T3","span":{"begin":150,"end":289},"obj":"Sentence"},{"id":"T4","span":{"begin":290,"end":411},"obj":"Sentence"},{"id":"T5","span":{"begin":412,"end":678},"obj":"Sentence"},{"id":"T6","span":{"begin":679,"end":762},"obj":"Sentence"},{"id":"T7","span":{"begin":763,"end":865},"obj":"Sentence"},{"id":"T8","span":{"begin":866,"end":954},"obj":"Sentence"},{"id":"T9","span":{"begin":955,"end":963},"obj":"Sentence"},{"id":"T10","span":{"begin":964,"end":1179},"obj":"Sentence"},{"id":"T11","span":{"begin":1180,"end":1314},"obj":"Sentence"},{"id":"T12","span":{"begin":1315,"end":1455},"obj":"Sentence"},{"id":"T13","span":{"begin":1456,"end":1556},"obj":"Sentence"},{"id":"T14","span":{"begin":1557,"end":1660},"obj":"Sentence"},{"id":"T15","span":{"begin":1661,"end":1672},"obj":"Sentence"},{"id":"T16","span":{"begin":1673,"end":1794},"obj":"Sentence"},{"id":"T17","span":{"begin":1795,"end":1862},"obj":"Sentence"}],"text":"1,25-dihydroxyvitamin D3 and dexamethasone increase interleukin-10 production in CD4+ T cells from patients with Crohn's disease.\nBACKGROUND AND AIM: In Crohn's disease (CD), epidemiological data and animal studies suggest that vitamin D (vitD) has protective immune-modulating properties. 1,25-dihydroxyvitamin D3 and dexamethasone (DEX) induce interleukin (IL)-10 productions in healthy controls (HC) T cells. We studied if 1,25-dihydroxyvitamin D3 with and without DEX could induce IL-10 production, downregulate pro-inflammatory Interferon (IFN)-gamma and Tumor Necrosis Factor (TNF)-alpha production, and influence cell kinetics in peripheral CD4+ T cells from CD patients.\nMETHODS: CD4+ T cells were separated from peripheral blood from CD patients and HC. Cells were activated by anti-CD3 and anti-CD28 in the presence of 1,25-dihydroxyvitamin D3 and/or DEX. Cytokine levels, proliferation, and apoptosis were measured following 7 days of culture.\nRESULTS: In T cells from CD patients, 1,25-dihydroxyvitamin D3 and DEX increased IL-10 production from a median of 0.08 ng/ml to 0.2 ng/ml (p\u003c0.01) and downregulated IFN-gamma production from 8.3 ng/ml to 3.1 ng/ml (p\u003c0.01). The induced IL-10 increase in cultures from HC (0.2 ng/ml to 1.0 ng/ml, p\u003c0.01) was significantly higher than in CD patients (p\u003c0.05). In CD cultures, the IL-4 production increased from 0.3 ng/ml to 0.5 ng/ml (p\u003c0.01) and IL-6 production from 2.5 ng/ml to 6.1 ng/ml (p\u003c0.05). Similar changes in cytokine levels were observed with 1,25-dihydroxyvitamin D3 independently of DEX. In addition, 1,25-dihydroxyvitamin D3 and DEX decreased proliferation and reduced viability of T cells.\nCONCLUSION: We found that 1,25-dihydroxyvitamin D3 with and without DEX stimulation increased IL-10 and reduced IFN-gamma production. These findings suggest that vitD may play a therapeutic role in CD."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":153,"end":168},"obj":"HP_0100280"},{"id":"T2","span":{"begin":560,"end":565},"obj":"HP_0002664"}],"text":"1,25-dihydroxyvitamin D3 and dexamethasone increase interleukin-10 production in CD4+ T cells from patients with Crohn's disease.\nBACKGROUND AND AIM: In Crohn's disease (CD), epidemiological data and animal studies suggest that vitamin D (vitD) has protective immune-modulating properties. 1,25-dihydroxyvitamin D3 and dexamethasone (DEX) induce interleukin (IL)-10 productions in healthy controls (HC) T cells. We studied if 1,25-dihydroxyvitamin D3 with and without DEX could induce IL-10 production, downregulate pro-inflammatory Interferon (IFN)-gamma and Tumor Necrosis Factor (TNF)-alpha production, and influence cell kinetics in peripheral CD4+ T cells from CD patients.\nMETHODS: CD4+ T cells were separated from peripheral blood from CD patients and HC. Cells were activated by anti-CD3 and anti-CD28 in the presence of 1,25-dihydroxyvitamin D3 and/or DEX. Cytokine levels, proliferation, and apoptosis were measured following 7 days of culture.\nRESULTS: In T cells from CD patients, 1,25-dihydroxyvitamin D3 and DEX increased IL-10 production from a median of 0.08 ng/ml to 0.2 ng/ml (p\u003c0.01) and downregulated IFN-gamma production from 8.3 ng/ml to 3.1 ng/ml (p\u003c0.01). The induced IL-10 increase in cultures from HC (0.2 ng/ml to 1.0 ng/ml, p\u003c0.01) was significantly higher than in CD patients (p\u003c0.05). In CD cultures, the IL-4 production increased from 0.3 ng/ml to 0.5 ng/ml (p\u003c0.01) and IL-6 production from 2.5 ng/ml to 6.1 ng/ml (p\u003c0.05). Similar changes in cytokine levels were observed with 1,25-dihydroxyvitamin D3 independently of DEX. In addition, 1,25-dihydroxyvitamin D3 and DEX decreased proliferation and reduced viability of T cells.\nCONCLUSION: We found that 1,25-dihydroxyvitamin D3 with and without DEX stimulation increased IL-10 and reduced IFN-gamma production. These findings suggest that vitD may play a therapeutic role in CD."}

{"project":"Ab3P-abbreviations","denotations":[{"id":"SF0","span":{"begin":170,"end":172},"obj":"ABBR"},{"id":"LF0","span":{"begin":153,"end":168},"obj":"ABBR"},{"id":"SF1","span":{"begin":239,"end":243},"obj":"ABBR"},{"id":"LF1","span":{"begin":228,"end":237},"obj":"ABBR"},{"id":"SF2","span":{"begin":334,"end":337},"obj":"ABBR"},{"id":"LF2","span":{"begin":319,"end":332},"obj":"ABBR"},{"id":"SF3","span":{"begin":359,"end":361},"obj":"ABBR"},{"id":"LF3","span":{"begin":346,"end":357},"obj":"ABBR"},{"id":"SF4","span":{"begin":399,"end":401},"obj":"ABBR"},{"id":"LF4","span":{"begin":381,"end":397},"obj":"ABBR"},{"id":"SF5","span":{"begin":545,"end":548},"obj":"ABBR"},{"id":"LF5","span":{"begin":533,"end":543},"obj":"ABBR"},{"id":"SF6","span":{"begin":583,"end":586},"obj":"ABBR"},{"id":"LF6","span":{"begin":560,"end":581},"obj":"ABBR"}],"relations":[{"id":"R0","pred":"ShortForm","subj":"LF0","obj":"SF0"},{"id":"R1","pred":"ShortForm","subj":"LF1","obj":"SF1"},{"id":"R2","pred":"ShortForm","subj":"LF2","obj":"SF2"},{"id":"R3","pred":"ShortForm","subj":"LF3","obj":"SF3"},{"id":"R4","pred":"ShortForm","subj":"LF4","obj":"SF4"},{"id":"R5","pred":"ShortForm","subj":"LF5","obj":"SF5"},{"id":"R6","pred":"ShortForm","subj":"LF6","obj":"SF6"}],"text":"1,25-dihydroxyvitamin D3 and dexamethasone increase interleukin-10 production in CD4+ T cells from patients with Crohn's disease.\nBACKGROUND AND AIM: In Crohn's disease (CD), epidemiological data and animal studies suggest that vitamin D (vitD) has protective immune-modulating properties. 1,25-dihydroxyvitamin D3 and dexamethasone (DEX) induce interleukin (IL)-10 productions in healthy controls (HC) T cells. We studied if 1,25-dihydroxyvitamin D3 with and without DEX could induce IL-10 production, downregulate pro-inflammatory Interferon (IFN)-gamma and Tumor Necrosis Factor (TNF)-alpha production, and influence cell kinetics in peripheral CD4+ T cells from CD patients.\nMETHODS: CD4+ T cells were separated from peripheral blood from CD patients and HC. Cells were activated by anti-CD3 and anti-CD28 in the presence of 1,25-dihydroxyvitamin D3 and/or DEX. Cytokine levels, proliferation, and apoptosis were measured following 7 days of culture.\nRESULTS: In T cells from CD patients, 1,25-dihydroxyvitamin D3 and DEX increased IL-10 production from a median of 0.08 ng/ml to 0.2 ng/ml (p\u003c0.01) and downregulated IFN-gamma production from 8.3 ng/ml to 3.1 ng/ml (p\u003c0.01). The induced IL-10 increase in cultures from HC (0.2 ng/ml to 1.0 ng/ml, p\u003c0.01) was significantly higher than in CD patients (p\u003c0.05). In CD cultures, the IL-4 production increased from 0.3 ng/ml to 0.5 ng/ml (p\u003c0.01) and IL-6 production from 2.5 ng/ml to 6.1 ng/ml (p\u003c0.05). Similar changes in cytokine levels were observed with 1,25-dihydroxyvitamin D3 independently of DEX. In addition, 1,25-dihydroxyvitamin D3 and DEX decreased proliferation and reduced viability of T cells.\nCONCLUSION: We found that 1,25-dihydroxyvitamin D3 with and without DEX stimulation increased IL-10 and reduced IFN-gamma production. These findings suggest that vitD may play a therapeutic role in CD."}